Search Results for: gadolinium

Published on:

Two FDA committees met yesterday to discuss the future of gadolinium warnings. Gadolinium is a contrast dye given to some patients before MRIs and MRAs that better highlights damaged parts of the body. Unfortunately, when given to patients with impaired renal function, it can be deadly. The committees recommended that two particular brands of gadolinium […]

Published on:

A new article on Business Week came out yesterday on gadolinium, with the focus on GE. First, a little background: Gadolinium is a metal that is injected as a contrast agent into patients before specific diagnostic tests, MRIs and MRAs. The metal allows physicians to better visualize damaged parts of the body. Most of us […]

Published on:

Okay, it’s a bad play on words. Bayer (you know them b/c they also make Gadolinium, the subject of other lawsuits) has just lost the fifth straight trial over long-grain rice crops. The Washington Post detailed the overwhelmingly successful efforts of farmers to prove to juries that Bayer’s genetically engineered seeds were contaminated, causing U.S. […]

Posted in:
Published on:
Updated:
Published on:

Here are the week’s stories: Adverse Events: Our friends at the US Recall News have a link to governmental agencies in charge of adverse event complaints and concerns. Avandia: Lots of concern recently about diabetes drug Avandia and heart problems (HT: Nursing Home Abuse Blog). Iqbal: The Lewis & Clark law review released its symposium […]

Published on:

Instead of doing our usual Monday Drug Blog Round-Up yesterday, we opted for a fuller post on the recent plaintiffs’ pain pump victory in Oregon. For more on that story, see the Oregonian. So, today we’ll bring you the links to the stories we’re following: Direct-to-Consumer Advertising: FiercePharma lists the top ten drugs for percentage […]

Published on:

The 406 YAZ, Yasmin and Ocella cases filed or transferred to the Southern District of Illinois before Judge David R. Herndon are proceeding apace. The Judge has been primarily concerned with case management and establishing procedures that will guide the litigation through to completion, including potentially bellwether trials (early trials that can reveal case strengths […]

Published on:

First, Merry Christmas and happy holidays to those who celebrate. And now–to work. The Drug and Device blog is continuing without the assistance of Mark Herrmann. Jim Beck posts on the Top Ten Best Prescription Drug/Medical Device Decisions Of 2009. From our side of the “v.” this can fairly be read as some of the […]

Published on:

It’s a winter wonderland here in Maryland, and our office is running on a skeleton crew. Here are the top drug injury-related stories for the past few days: Digitek: Tom Lamb and the Drug Injury Watch post on the status of this litigation (surprisingly, it is not defunct yet, despite long problems in finding the […]

Published on:

Not drug related, but Happy Anniversary is in order. Now that you know more about me than you are probably comfortable with (who celebrates that?), let’s get to business with some noteworthy items: Reuters discusses the FDAs investigation of using drugs like Seroquel on children. Recently expanded indications for Seroquel by children. The Chicago Tribune […]